Patents by Inventor Bernard Christophe Barlaam
Bernard Christophe Barlaam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190099421Abstract: This specification generally relates to compounds of Formula (I): And pharmaceutically acceptable salts thereof, where R1, R2 and R3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts thereof; kits comprising such compounds and salts thereof; methods of manufacture of such compounds and salts thereof; intermediates useful in the manufacture of such compounds and salts thereof; and to methods of treating ATM kinase mediated disease, including cancer, using compounds of Formula (I) and salts thereof alone or in combination with other therapies.Type: ApplicationFiled: March 20, 2017Publication date: April 4, 2019Inventors: Kurt Gordon PIKE, Bernard Christophe BARLAAM
-
Publication number: 20190100520Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: October 9, 2018Publication date: April 4, 2019Inventors: Bernard Christophe BARLAAM, Daniel Hillebrand O'DONOVAN, Samantha Jayne HUGHES, Thomas Andrew MOSS, Johannes Wilhelmus Maria NISSINK, James Stewart SCOTT, Bin YANG
-
Patent number: 10221173Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: GrantFiled: January 29, 2018Date of Patent: March 5, 2019Assignee: AstraZeneca ABInventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
-
Patent number: 10189834Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.Type: GrantFiled: October 17, 2017Date of Patent: January 29, 2019Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Kurt Gordon Pike
-
Patent number: 10149839Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: GrantFiled: July 24, 2017Date of Patent: December 11, 2018Assignee: AstraZeneca ABInventors: James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam, Dan Anders Broo, Bin Yang, Jeffrey Gilbert Varnes, Dedong Wu
-
Patent number: 10131663Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: GrantFiled: October 13, 2017Date of Patent: November 20, 2018Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Daniel Hillebrand O'Donovan, Samantha Jayne Hughes, Thomas Andrew Moss, Johannes Wilhelmus Maria Nissink, James Stewart Scott, Bin Yang
-
Patent number: 10125135Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: GrantFiled: April 19, 2017Date of Patent: November 13, 2018Assignee: AstraZeneca ABInventors: Bin Yang, Jeffrey Gilbert Varnes, James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam
-
Publication number: 20180318287Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where x, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.Type: ApplicationFiled: November 2, 2016Publication date: November 8, 2018Applicant: ASTRAZENECA ABInventors: Kurt Gordon PIKE, Bernard Christophe BARLAAM, Thomas Anthony HUNT, Andrew John EATHERTON
-
Publication number: 20180280377Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1, R2, R3 and R4 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.Type: ApplicationFiled: November 2, 2016Publication date: October 4, 2018Inventors: Kurt Gordon PIKE, Bernard Christophe BARLAAM, Thomas Anthony HUNT, Andrew John EATHERTON
-
Publication number: 20180282325Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: January 29, 2018Publication date: October 4, 2018Inventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
-
Publication number: 20180141943Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising to substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.Type: ApplicationFiled: November 27, 2017Publication date: May 24, 2018Applicant: AstraZeneca ABInventors: Bernard Christophe Barlaam, Kurt Gordon Pike, Andrew John Eatherton, Thomas Anthony Hunt
-
Publication number: 20180134699Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.Type: ApplicationFiled: October 17, 2017Publication date: May 17, 2018Inventors: Bernard Christophe BARLAAM, Kurt Gordon PIKE
-
Publication number: 20180111931Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: October 13, 2017Publication date: April 26, 2018Inventors: Bernard Christophe BARLAAM, Daniel Hillebrand O'DONOVAN, Samantha Jayne HUGHES, Thomas Andrew MOSS, Johannes Wilhelmus Maria NISSINK, James Stewart SCOTT, Bin YANG
-
Publication number: 20180021316Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: July 24, 2017Publication date: January 25, 2018Inventors: James Stewart Scott, Thomas Andrew Moss, Daniel Hillebrand O'Donovan, Johannes Wilhelmus Maria Nissink, Samantha Jayne Hughes, Bernard Christophe Barlaam, Dan Anders Broo, Bin Yang, Jeffrey Gilbert Varnes, Dedong Wu
-
Patent number: 9856255Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.Type: GrantFiled: September 16, 2016Date of Patent: January 2, 2018Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Kurt Gordon Pike
-
Patent number: 9822111Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.Type: GrantFiled: July 22, 2016Date of Patent: November 21, 2017Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Kurt Gordon Pike
-
Publication number: 20170305909Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: ApplicationFiled: April 19, 2017Publication date: October 26, 2017Inventors: Bin YANG, Jeffrey Gilbert VARNES, James Stewart SCOTT, Thomas Andrew MOSS, Daniel Hillebrand O'DONOVAN, Johannes Wilhelmus Maria NISSINK, Samantha Jayne HUGHES, Bernard Christophe BARLAAM
-
Patent number: 9718800Abstract: The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.Type: GrantFiled: March 24, 2016Date of Patent: August 1, 2017Assignee: ASTRAZENECA ABInventors: Bernard Christophe Barlaam, Sebastien Louis Degorce, Christine Marie Paul Lambert-Van Der Brempt, Remy Robert Morgentin, Patrick Ple
-
Patent number: 9657008Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.Type: GrantFiled: August 31, 2015Date of Patent: May 23, 2017Assignee: AstraZeneca ABInventors: Bernard Christophe Barlaam, Benedicte Delouvrie, Craig Steven Harris, Christine Marie Paul Lambert-Van der Brempt, Gilles Ouvry, Gary Patrick Reid, David Berry, Gary Peter Tomkinson
-
Publication number: 20170081325Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.Type: ApplicationFiled: September 16, 2016Publication date: March 23, 2017Applicant: AstraZeneca ABInventors: Bernard Christophe Barlaam, Andrew John Eatherton, Thomas Anthony Hunt, Kurt Gordon Pike